Buy Xovoltib : Afatinib 30 Mg Tablets 28’S Online

Description

Description:

Xovoltib is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and metastatic squamous cell carcinoma of the lung. It contains the active substance afatinib, which belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Here’s a detailed description:

1. Indications: Xovoltib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring specific mutations in the epidermal growth factor receptor (EGFR) gene, including exon 19 deletions or exon 21 (L858R) substitution mutations. It is also used for the treatment of metastatic squamous cell carcinoma of the lung that has progressed on or after platinum-based chemotherapy.
2. Active Substance:
   • Afatinib: Afatinib is a reversible inhibitor of the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. By blocking EGFR and other related receptors, afatinib interferes with signaling pathways involved in cell proliferation, survival, and angiogenesis, ultimately leading to inhibition of tumor growth and progression.
3. Dosage Form: Xovoltib is available in tablet form, with each tablet typically containing 30 mg of afatinib. It is commonly supplied in blister packs containing 28 tablets.
4. Dosage and Administration: The recommended dosage of Xovoltib may vary depending on the indication and the patient’s individual characteristics. It is usually taken orally once daily, at least one hour before or two hours after meals. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or divided.
5. Mechanism of Action: Afatinib exerts its therapeutic effects by selectively inhibiting the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR), HER2, and HER4. By blocking EGFR signaling pathways, afatinib interferes with tumor cell proliferation, survival, and angiogenesis, leading to inhibition of tumor growth and metastasis.
6. Benefits:
   • Treatment of NSCLC: Xovoltib offers a targeted treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, providing improved progression-free survival and overall survival outcomes compared to standard chemotherapy.
   • Treatment of Squamous Cell Carcinoma: In patients with metastatic squamous cell carcinoma of the lung that has progressed on or after platinum-based chemotherapy, Xovoltib provides a treatment option that may improve disease control and symptom management.
7. Side Effects: Common side effects associated with Xovoltib may include:
   • Diarrhea
   • Rash or skin irritation
   • Fatigue
   • Nausea and vomiting
   • Decreased appetite
   • Stomatitis (inflammation of the mouth)
   • Nail changes (such as discoloration or loss)
   • Dry skin or pruritus (itching)
8. Contraindications and Precautions: Xovoltib is contraindicated in individuals with known hypersensitivity to afatinib or any of its components. It should be used with caution in patients with certain medical conditions, such as hepatic impairment, renal impairment, or interstitial lung disease, due to the risk of exacerbating treatment-related adverse reactions.
9. Storage: Xovoltib tablets should be stored according to the manufacturer’s instructions, typically at room temperature away from light, heat, and moisture. Unused tablets should be kept in their original blister packaging until ready for use.

As with any cancer therapy, the use of Xovoltib should be supervised by a qualified healthcare provider experienced in the management of NSCLC and metastatic squamous cell carcinoma of the lung. Patients should receive education on proper dosing, potential side effects, and the importance of regular monitoring during treatment to optimize therapeutic outcomes and ensure patient safety. Close communication between patients, caregivers, and healthcare providers is essential for managing treatment-related side effects and addressing any concerns or questions that may arise.